Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
Christie Brinkley details how doctors found skin cancer
Christie Brinkley is opening up about her skin cancer diagnosis two months after she revealed she was diagnosed with the disease....
-
Is 3 feet enough for social distancing in schools? CDC looking into relaxing guidelines
The Centers for Disease Control and Prevention is looking into whether 6 feet of distance is necessary to keep...
-
Weight-loss drug Wegovy cuts risk of stroke and heart attacks, the drugmaker says
The popular obesity drug Wegovy cuts the risk of cardiovascular events, such as heart attack and stroke, by 20%,...
-
A week of food and water, plus child and pet care: How hospitals are prepping for Milton
As Hurricane Milton bears down on Florida, the staff at Sarasota Memorial Hospital is getting ready. The facility, in...
-
Tanya Roberts died from infection that caused sepsis
The actress Tanya Roberts died from a urinary tract infection that developed into sepsis, an outcome that is more...
-
What to know about Zepbound, Eli Lilly’s new weight loss drug
A new weight loss drug has been approved that promises to be the most effective medication yet. How is...
-
Cancer patients often do better with less intensive treatment, research shows
Scaling back treatment for three kinds of cancer can make life easier for patients without compromising outcomes, doctors reported...
-
Could the new mpox threat cause significant harm in the U.S.?
As concerns mount about a type of mpox spreading across Africa that’s believed to cause more serious illness, infectious...
Recent Comments